In a study conducted by Gupta et al., it was demonstrated that carfilzomib treatment in CLL primary cells had the unexpected effect of inducing the NF-κB pathway instead of inhibiting it. The gene discussed is NFKB1; the disease is B-cell chronic lymphocytic leukemia.